MS in the Media - 25 September 2020
19 - 25 September 2020
These are links to recent news stories about multiple sclerosis that may be of interest to people affected by MS in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter, or regular email alerts.
Myelin repair breakthrough
Repairing the damage to nerves caused by MS is possible, according to UK research, although the side effects of the particular drug used in the trial, bexarotene, mean that it is unsafe to be considered as a potential treatment
Source: Guardian
MS Trust link: Trial reports myelin repair success
Progressive MS results encouraging
Masitinib showed 'positive signs' in progressive forms of multiple sclerosis according to a French study. EDSS scores increased less quickly and the time to 'first progression' was longer than for people on a placebo
Source: MedPage Today
MS Trust link: Masitinib
Health changes before MS onset identified
People who go on to develop MS will start using health and mental health services more frequently in the 5 to 10 years before MS is recognised, according to Canadian research. This effects is called a prodrome.
Source: Healio
MS Trust link: Worried you might have MS?
US dental amalgam advice changed
The FDA, the US drug regulator, has reviewed its advice on dental amalgam fillings. Although they have found no evidence of danger from these fillings, and they don't recommend removal, they advise that certain groups, including people with pre-existing neurological disease should be offered alternative, non-mercury materials
Source: FDA
MS Trust link: Dental fillings
MS in the Media
27 Nov 2020 - 00:00
- Depression affects multitasking in MS
- Benefits process in Scotland
- Cancer risks and multiple sclerosis
- Gut immune cells and relapses
MS in the Media
20 Nov 2020 - 00:00
- New study for advanced MS
- Campaign for fair benefits during the pandemic
- Stem cells compared to Lemtrada
- DMD use and finances
David Martin appointed Chair of the Neurological Alliance
18 Nov 2020 - 00:00
The MS Trust is delighted to announce that CEO David Martin, has been voted in as Chair of the Neurological Alliance.
Sign up to our emails
Get the latest news and research sent straight to your inbox. Find out first about the latest developments in MS treatments, plus updates on the work of the MS Trust.
Share
